Loading…
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $81M | $-88M | $-143M | $-141M | 76.7% | 14.9% | - |
| 2024 | $71M | $-103M | $-158M | $-125M | 77.9% | 1.8% | - |
| 2023 | $70M | $-146M | $-240M | $-122M | 161.9% | -66.9% | - |
| 2022 | $210M | $-108M | $-157M | $-139M | -197.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 209.91 | 69.56 | 70.84 | 81.36 |
| Cost Of Revenue | 3.30 | 2.53 | 5.95 | 5.80 |
| Gross Profit | 206.61 | 67.03 | 64.89 | 75.56 |
| Operating Expense | 329.59 | 232.08 | 194.48 | 182.77 |
| Operating Income | -122.99 | -165.05 | -129.59 | -107.21 |
| EBITDA | -107.70 | -145.83 | -102.65 | -88.10 |
| EBIT | -110.09 | -149.09 | -105.92 | -89.97 |
| Pretax Income | -146.82 | -195.42 | -156.14 | -141.61 |
| Tax Provision | 0.23 | 39.11 | 0.17 | 1.01 |
| Net Income | -157.13 | -240.05 | -157.85 | -142.62 |
| Net Income Common Stockholders | -157.13 | -240.05 | -157.85 | -142.62 |
| Total Expenses | 332.89 | 234.61 | 200.43 | 188.56 |
| Interest Expense | 36.73 | 46.33 | 50.21 | 51.63 |
| Interest Income | 2.57 | 10.54 | 12.27 | 8.81 |
| Research And Development | 186.46 | 127.13 | 109.63 | 104 |
| Selling General And Administration | 143.49 | 105.89 | 85.91 | 79.93 |
| Normalized EBITDA | -91.12 | -145.78 | -102.57 | -74.31 |
| Normalized Income | -144.04 | -240.01 | -157.78 | -131.73 |
| Basic EPS | -1.99 | -2.94 | -1.62 | 0 |
| Diluted EPS | -1.99 | -2.94 | -1.62 | 0 |
| Tax Effect Of Unusual Items | -3.48 | -0.01 | -0.02 | -2.90 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -16.57 | -0.05 | -0.08 | -13.79 |
| Total Unusual Items Excluding Goodwill | -16.57 | -0.05 | -0.08 | -13.79 |
| Net Income From Continuing Operation Net Minority Interest | -157.13 | -240.05 | -157.85 | -142.62 |
| Reconciled Depreciation | 2.39 | 3.27 | 3.28 | 1.88 |
| Reconciled Cost Of Revenue | 3.30 | 2.53 | 5.95 | 5.80 |
| Net Interest Income | -34.16 | -35.78 | -37.94 | -42.82 |
| Net Income From Continuing And Discontinued Operation | -157.13 | -240.05 | -157.85 | -142.62 |
| Total Operating Income As Reported | -123.34 | -165.99 | -130.65 | -121.50 |
| Diluted Average Shares | 78.15 | 81.71 | 97.16 | 0 |
| Basic Average Shares | 78.15 | 81.71 | 97.16 | 0 |
| Diluted NI Availto Com Stockholders | -157.13 | -240.05 | -157.85 | -142.62 |
| Net Income Including Noncontrolling Interests | -157.13 | -240.05 | -157.85 | -142.62 |
| Net Income Continuous Operations | -157.13 | -240.05 | -157.85 | -142.62 |
| Earnings From Equity Interest Net Of Tax | -10.08 | -5.53 | -1.54 | 0 |
| Other Income Expense | 10.33 | 5.42 | 11.39 | 8.42 |
| Other Non Operating Income Expenses | 26.91 | 5.47 | 11.47 | 22.21 |
| Special Income Charges | -42.11 | 0 | 0 | -13.12 |
| Other Special Charges | 42.11 | 0 | 0 | 1.33 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 5.75 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 6.03 |
| Earnings From Equity Interest | -10.08 | 0 | 0 | 0 |
| Gain On Sale Of Security | 25.54 | -0.05 | -0.08 | -0.67 |
| Net Non Operating Interest Income Expense | -34.16 | -35.78 | -37.94 | -42.82 |
| Interest Expense Non Operating | 36.73 | 46.33 | 50.21 | 51.63 |
| Interest Income Non Operating | 2.57 | 10.54 | 12.27 | 8.81 |
| Other Taxes | -0.36 | -0.94 | -1.06 | -1.17 |
| Selling And Marketing Expense | 35.75 | 33.01 | 21.44 | 19.48 |
| General And Administrative Expense | 107.74 | 72.88 | 64.47 | 60.45 |
| Other Gand A | 25.98 | 20.54 | 17.68 | 13.91 |
| Salaries And Wages | 81.76 | 52.34 | 46.78 | 46.53 |
| Operating Revenue | 209.91 | 69.56 | 70.84 | 81.36 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ADC Therapeutics SAthis co. | ADCT | $481M | - | -2.56 | 76.7% | -6.25 |
| XOMA Royalty Corporation | XOMA | $497M | 28.08 | 5.79 | 37.8% | 38.75 |
| Entrada Therapeutics, Inc. | TRDA | $494M | - | 1.50 | -47.0% | -1.40 |
| Esperion Therapeutics, Inc. | ESPR | $492M | - | -1.55 | 7.5% | 14.42 |
| Fulcrum Therapeutics, Inc. | FULC | $476M |
| - |
| 1.36 |
| -21.5% |
| -1.75 |
| Verastem, Inc. | VSTM | $474M | - | 7.34 | -366.2% | -2.10 |
| agilon health, inc. | AGL | $465M | - | 3.65 | -308.8% | -0.53 |
| Ginkgo Bioworks Holdings, Inc. | DNA | $464M | - | 0.86 | -61.5% | -1.69 |
| Varex Imaging Corporation | VREX | $462M | - | 0.97 | -14.4% | 7.73 |
| Peer Median | - | 28.08 | 1.43 | -34.2% | -0.97 | |